Last week, readers were most interested in a story about Diasorin's submission to FDA for its POC testing instrument.

Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

The Glasgow, Scotland-based firm's Panaromic Platform uses an infrared spectroscopy-based test with machine learning-developed algorithms to detect signals of cancer.

A lab owner, marketing firm owner, and doctor have been sentenced to between 13 months and five years in prison for their roles in a multimillion-dollar lab fraud scheme.

Lund, Sweden-based Qlucore aims to have bladder cancer and AML tests available for clinical use in Europe by 2027.

NEW YORK – After months of declining share prices, diagnostics firm got a reprieve in June as the 360 Top 30 rose nearly 6 percent month over month. The Top 30 mirrored the broader markets as the Dow ...